Successful Treatment of Hemodynamic Compromise Caused by Antibody-Mediated and Cellular Rejection in a Recipient 12 years After Heart Transplantation-Reference-Cited by-同舟云学术

Successful Treatment of Hemodynamic Compromise Caused by Antibody-Mediated and Cellular Rejection in a Recipient 12 years After Heart Transplantation

Published:2013 Issue:5 Volume:54 Page:328-331
ISSN:1349-2365
Container-title:International Heart Journal
language:en
Short-container-title:Int. Heart J.

Author:

Imamura Teruhiko¹,Kinugawa Koichiro²,Kato Naoko¹,Kagami Yukie³,Endo Miyoko³,Kaneko Nobuyuki⁴,Minatsuki Shun¹,Muraoka Hironori¹,Inaba Toshiro¹,Maki Hisataka¹,Hatano Masaru¹,Doi Kent⁵,Yao Atsushi¹,Takazawa Yutaka⁴,Ono Minoru⁶,Kyo Shunei²,Komuro Issei¹

Affiliation:

1. Department of Cardiovascular Medicine, Graduate School of Medicine, the University of Tokyo

2. Department of Therapeutic Strategy for Heart Failure, Graduate School of Medicine, the University of Tokyo

3. Department of Organ Transplantation, Graduate School of Medicine, the University of Tokyo

4. Department of Pathology, Graduate School of Medicine, the University of Tokyo

5. Department of Nephrology and Endocrinology, Graduate School of Medicine, the University of Tokyo

6. Department of Cardiothoracic Surgery, Graduate School of Medicine, the University of Tokyo

Publisher

International Heart Journal (Japanese Heart Journal)

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Link

https://www.jstage.jst.go.jp/article/ihj/54/5/54_328/_pdf

Reference13 articles.

1. 1. Chin C. Cardiac antibody-mediated rejection. Pediatr Transplant 2012; 16: 404-12. (Review)

2. 2. Colvin RB, Smith RN. Antibody-mediated organ-allograft rejection. Nat Rev Immunol 2005; 5: 807-17. (Review)

3. 3. Michaels PJ, Espejo ML, Kobashigawa J, et al. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant 2003; 22: 58-69.

4. 4. Fishbein MC, Kobashigawa J. Biopsy-negative cardiac transplant rejection: etiology, diagnosis, and therapy. Curr Opin Cardiol 2004; 19: 166-9. (Review)

5. 5. Aranda JM Jr, Scornik JC, Normann SJ, et al. Anti-CD20 monoclonal antibody (rituximab) therapy for acute cardiac humoral rejection: a case report. Transplantation 2002; 73: 907-10.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase II clinical trial testing the safety of a humanised monoclonal antibody anti-CD20 in patients with heart failure with reduced ejection fraction, ICFEr-RITU2: study protocol;BMJ Open;2019-03

2. Rituximab Therapy for Rejection in Pediatric Heart Transplant;Experimental and Clinical Transplantation;2018-04

3. Late Rejection Occurred in Recipients Who Experienced Acute Cellular Rejection Within the First Year After Heart Transplantation;International Heart Journal;2015

4. Coronary Pan-Ischemia as a First Sign of a Fulminant Host-Versus-Graft Reaction Eight Years After Orthotopic Heart Transplantation;International Heart Journal;2015

5. How Should We Treat Early Post-Transplant Lymphoproliferative Disease After Heart Transplantation?;International Heart Journal;2015